Effectiveness and Safety of Lactobacillus Rhamnosus Lcr35® in the Treatment of Recurrent Aphthous Stomatitis
Status:
Completed
Trial end date:
2020-07-15
Target enrollment:
Participant gender:
Summary
Recurrent aphthous stomatitis (RAS) is a frequent condition characterized by recurrent and
painful oral ulcers with unknown pathophysiology. Recent studies suggest that a dysregulation
of the oral microbiota may be implicated. Currently, therapies for RAS are limited by severe
side effects or inconstant effectiveness. The aim of this study is to assess the
effectiveness and safety of a probiotic, the Lactobacillus rhamnosus Lcr35® , in the
treatment of RAS. A placebo-controlled, parallel study will be conducted in 40 subjects with
RAS. Treatment consisted on the administration of the daily probiotics or placebo during 3
months.All patients will be then followed up for additional 3months without treatment. The
main outcome measure will be the number of occurring aphtae.